| I-018 Asma Baliouze Exposure-Response Analysis of Centanafadine Sustained Release Tablets in Adults with Attention-Deficit/Hyperactivity Disorder Wednesday 10:20-11:50 |
| I-032 Monir Bertayli PK-PD model of morphine, pregabalin and their combination to assess the opioid-sparing effect Wednesday 10:20-11:50 |
| I-061 Lu Chen Time-dependent pharmacokinetics of hydromethylthionine mesylate (HMTM), a tau aggregation inhibitor, in healthy volunteers and patients with Alzheimer's Disease Wednesday 10:20-11:50 |
| I-113 Aline Fuchs Human dose prediction approach for a therapeutic monoclonal antibody for a CNS indication inferred using preclinical data including target occupancy Wednesday 10:20-11:50 |
| II-005 Mohamed Gewily Quantitative comparisons of Progressive Supranuclear Palsy rating scales versions using Item Response Theory modeling Wednesday 15:20-16:50 |
| II-039 Maria Patricia Hernandez Mitre Population pharmacokinetics of olanzapine and quetiapine in critically ill adults with delirium Wednesday 15:20-16:50 |
| II-049 Silvia Illamola Population analysis of blood-brain barrier heterogeneity and correlation with imaging characteristics in individuals with central nervous system malignancies. Wednesday 15:20-16:50 |
| III-007 Victor Mangas-Sanjuan Pharmacometric characterization of the reserpine-induced fibromyalgia model in rats to support a model-informed dosing regimen strategy for alternative disease status conditions Thursday 09:50-11:20 |
| III-062 Noel Patson Natural disease progression model with transition probabilities to describes the continuum of Alzheimer’s disease Thursday 09:50-11:20 |
| III-066 Carlos Perez-Ruixo A Mechanism-Based PK/PD Model for Posdinemab (JNJ-63733657), a Humanized Monoclonal Antibody Targeting pTau, in healthy and Alzheimer’s Disease Subjects Thursday 09:50-11:20 |
| III-094 Elena Righetti A mechanistic model of pure and lipid-mediated alpha-synuclein aggregation to advance therapeutic strategies against Parkinson’s disease Thursday 09:50-11:20 |
| III-101 Chiara Roversi Integrated Population PK and PBPK Modelling Approaches of IAMA-6 Plasma Concentrations following Oral, Intraperitoneal and Intravenous Administrations in Three Different Preclinical Species for First in Human Dose Prediction Thursday 09:50-11:20 |
| IV-023 ming sun Bayesian PBPK modeling for acyclovir dose optimization for treating viral encephalitis Thursday 15:00-16:30 |
| IV-056 Marloes van Leuken A population pharmacokinetic model of N,N-dimethyltryptamine administered through continuous intravenous infusion in healthy smokers and non-smokers Thursday 15:00-16:30 |
| IV-106 Mengxu Zhang Exploring the contribution of brain metabolism in mechanistic understanding of Kp,uu,BBB – A case study for remoxipride Thursday 15:00-16:30 |
